IRIS Trial

18 Aug, 10

Comparison of safety and efficacy of Rosuvastatin versus atorvastatin in South-Asian patients at risk of Coronary Heart Disease

Objective

To compare the lipid-lowering effects of rosuvastatin as compared to atorvastatin in South-Asian patients.

N=740; Patients of South-Asian origin with dyslipidemia and at high risk of coronary heart disease.

Patients were randomized to receive 1 of the 4 treatment options once-daily: Rosuvastatin 10 or 20 mg and Atorvastatin 10 or 20 mg.

6 weeks

Rosuvastatin resulted in greater improvement in lipid parameters as compared to atorvastatin.

There were no clinically relevant differences between statins in adverse events or incidence of CK>10 times the ULN, liver enzymes>3 times the ULN on 2 consecutive occasions, or proteinuria or hematuria during treatment.

Rosuvastatin therapy was effective and well tolerated in patients of South-Asian origin.

Am J Cardiol 2007; 99: 1538-4